Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Bill Wexler's Dog Pound -- Ignore unavailable to you. Want to Upgrade?

To: BelowTheCrowd who wrote (1354)	6/15/1999 12:38:00 AM
From: R. M. Rosenthal	Read Replies (2) \| Respond to of 10293

"The payments are tied to the company reaching various 'milestones,'' such as the drug performing well in animal tests, reaching human trials and getting Food and Drug Administration approvals." Your analogy weak: CCSI breakthrough techonolgy is well past preliminary 'milestones,' FDA-cleared, patented, already in use in dozens of major hospitals nationwide & about to be aggresssively distributed by Ohmeda Medical, one of world's most trusted and respected neonatal products innovator, manufacturer, supplier-servicer + US$8MM equity investment from Lehman Bros. Res ipsa loquitor, IMO